Overview
Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases. It is marketed under the name Eliquis. Apixaban was approved by the FDA on December 28, 2012.
Indication
Apixaban is indicated for reducing the risk of stroke and systemic embolism in patients who have nonvalvular atrial fibrillation, prophylaxis of deep vein thrombosis(DVT) leading to pulmonary embolism(PE) in patients after a hip or knee replacement surgery, and treatment of DVT and PE to reduce the risk of recurrence.
Associated Conditions
- Deep Vein Thrombosis
- Deep vein thrombosis recurrent
- Pulmonary Embolism
- Recurrent Pulmonary Embolism (Disorder)
- Stroke
- Systemic Embolism
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2025/06/11 | Phase 3 | Not yet recruiting | |||
2025/05/01 | Phase 4 | Not yet recruiting | |||
2025/03/20 | Early Phase 1 | Recruiting | Rushad Patell | ||
2024/12/19 | Phase 3 | Recruiting | |||
2024/12/11 | Phase 2 | Not yet recruiting | Oslo University Hospital | ||
2024/10/21 | Phase 4 | Not yet recruiting | Emily McDonald | ||
2024/09/20 | N/A | Completed | Abu Dhabi Health Services Company | ||
2024/09/19 | Phase 4 | Recruiting | |||
2024/08/13 | Phase 3 | Recruiting | |||
2024/07/31 | Phase 3 | Recruiting |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 0003-0894 | ORAL | 5 mg in 1 1 | 3/2/2018 | |
| Bryant Ranch Prepack | 63629-7747 | ORAL | 5 mg in 1 1 | 1/17/2022 | |
| A-S Medication Solutions | 50090-6454 | ORAL | 5 mg in 1 1 | 3/2/2018 | |
| N/A | 82982-054 | ORAL | 5 mg in 1 1 | 2/21/2023 | |
| E.R. Squibb & Sons, L.L.C. | 0003-0893 | ORAL | 2.5 mg in 1 1 | 3/2/2018 | |
| Indoco Remedies Limited | 14445-149 | ORAL | 2.5 mg in 1 1 | 6/15/2021 | |
| A-S Medication Solutions | 50090-1436 | ORAL | 2.5 mg in 1 1 | 3/2/2018 | |
| Cardinal Health 107, LLC | 55154-0612 | ORAL | 2.5 mg in 1 1 | 11/8/2018 | |
| Aphena Pharma Solutions - Tennessee, LLC | 71610-662 | ORAL | 5 mg in 1 1 | 2/1/2023 | |
| Indoco Remedies Limited | 14445-150 | ORAL | 5 mg in 1 1 | 6/15/2021 |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
Authorised | 7/23/2020 | ||
Authorised | 5/18/2011 |
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| DCLOT 2.5 FILM COATED TABLETS 2.5 MG | SIN16675P | TABLET, FILM COATED | 2.5mg | 1/11/2023 | |
| Eliquis Tablet 2.5mg | SIN14279P | TABLET, FILM COATED | 2.5mg | 12/24/2012 | |
| DCLOT 5 FILM COATED TABLETS 5 MG | SIN16674P | TABLET, FILM COATED | 5mg | 1/11/2023 | |
| ELIQUIS TABLET 5MG | SIN14407P | TABLET, FILM COATED | 5mg | 9/11/2013 |
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| Apixaban Tablets | 国药准字HJ20170236 | 化学药品 | 片剂 | 9/27/2022 | |
| Apixaban Tablets | 国药准字H20213937 | 化学药品 | 片剂 | 12/14/2021 | |
| Apixaban Tablets | 国药准字H20193003 | 化学药品 | 片剂 | 9/1/2023 | |
| Apixaban Tablets | 国药准字H20249321 | 化学药品 | 片剂 | 11/15/2024 | |
| Apixaban Tablets | 国药准字H20213468 | 化学药品 | 片剂 | 6/8/2021 | |
| Apixaban Tablets | 国药准字H20223258 | 化学药品 | 片剂 | 4/27/2022 | |
| Apixaban Tablets | 国药准字H20213064 | 化学药品 | 片剂 | 1/30/2021 | |
| Apixaban Tablets | 国药准字H20223491 | 化学药品 | 片剂 | 7/7/2022 | |
| Apixaban Tablets | 国药准字H20234292 | 化学药品 | 片剂 | 10/12/2023 | |
| Apixaban Tablets | 国药准字H20223338 | 化学药品 | 片剂 | 5/25/2022 |
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| APO-APIXABAN TABLETS 2.5MG | N/A | N/A | N/A | 11/21/2024 | |
| APO-APIXABAN TABLETS 5MG | N/A | N/A | N/A | 11/21/2024 |
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| APIBIC apixaban 5 mg film coated tablet blister pack | 444073 | Medicine | A | 2/11/2025 | |
| APIXIBIC apixaban 5 mg film coated tablet blister pack | 444083 | Medicine | A | 2/11/2025 | |
| APIXABAN APPL apixaban 2.5 mg film coated tablet blister pack | 444076 | Medicine | A | 2/11/2025 | |
| ELAPEX apixaban 5 mg tablet blister pack | 428663 | Medicine | A | 12/3/2024 | |
| ELIQUIS apixaban 5 mg film-coated tablet blister pack | 193474 | Medicine | A | 5/2/2013 | |
| APIXABAN LAPL apixaban 5 mg tablet blister pack | 392234 | Medicine | A | 5/23/2025 | |
| APIBIC apixaban 2.5 mg film coated tablet blister pack | 444072 | Medicine | A | 2/11/2025 | |
| APIXABAN APL apixaban 5 mg film coated tablet blister pack | 444081 | Medicine | A | 2/11/2025 | |
| AXIBIC apixaban 5 mg film coated tablet blister pack | 444089 | Medicine | A | 2/11/2025 | |
| ELIBIC apixaban 2.5 mg film coated tablet blister pack | 444086 | Medicine | A | 2/11/2025 |
Help Us Improve
Your feedback helps us provide better drug information and insights.